1. Home
  2. CTW vs IPHA Comparison

CTW vs IPHA Comparison

Compare CTW & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CTW Cayman Class A Ordinary Shares

CTW

CTW Cayman Class A Ordinary Shares

N/A

Current Price

$2.20

Market Cap

171.0M

Sector

Technology

ML Signal

N/A

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

N/A

Current Price

$1.59

Market Cap

165.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CTW
IPHA
Founded
2013
1999
Country
Japan
France
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
171.0M
165.3M
IPO Year
2025
2014

Fundamental Metrics

Financial Performance
Metric
CTW
IPHA
Price
$2.20
$1.59
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $6.67
AVG Volume (30 Days)
20.5K
★ 51.6K
Earning Date
10-15-2026
09-17-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$390.56
Revenue Next Year
N/A
$143.06
P/E Ratio
$22.41
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.10
$1.18
52 Week High
$3.14
$2.71

Technical Indicators

Market Signals
Indicator
CTW
IPHA
Relative Strength Index (RSI) 48.02 27.90
Support Level $2.09 $1.34
Resistance Level $3.02 $1.57
Average True Range (ATR) 0.18 0.10
MACD 0.01 -0.02
Stochastic Oscillator 63.55 0.00

Price Performance

Historical Comparison
CTW
IPHA

About CTW CTW Cayman Class A Ordinary Shares

CTW operates as a gaming platform company providing instant access to free-to-play, browser-based games inspired by popular Japanese animation, including "So I'm a Spider, So What? Ruler of the Labyrinth, Arifureta: From Commonplace to World's Strongest - Rebellion Soul", and "Queen's Blade Limit Break". CTW delivers these games through its flagship HTML5 platform, G123.jp.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Share on Social Networks: